Gonorrhea Male
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Aurum BiosciencesUK - Glasgow
1 program1
WHO-recommended periodic presumptive treatmentPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Aurum BiosciencesWHO-recommended periodic presumptive treatment
Allergy TherapeuticsPay-it-forward
Clinical Trials (2)
Total enrollment: 3,201 patients across 2 trials
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Start: Oct 2025Est. completion: Apr 20292,900 patients
Phase 4Recruiting
Pay-it-forward RCT for Gonorrhea and Chlamydia Testing
Start: Dec 2018Est. completion: Sep 2019301 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 3,201 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.